Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer

Summary

This phase II trial tests whether regorafenib and durvalumab work to shrink tumors in patients with high-risk liver cancer. Regorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving regorafenib and durvalumab may work better in treating patients with high-risk liver cancer.

Timeline

Start

2023-07-01

Primary completion

2025-12-05

Completion

2028-12-05

Drugs

Indications